A father and his son with systemic AL amyloidosis

In systemic AL amyloidosis, fibrils are derived from a monoclonal immunoglobulin light chain produced by a plasma cell clone in the bone marrow.[1][1] AL amyloidosis may be associated with multiple myeloma but more commonly the plasma cell clone is not malignant. A monoclonal gammopathy of

[1]  Y. Chung,et al.  Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers , 2008, Clinical Cancer Research.

[2]  R. Wilson,et al.  Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. , 2008, Blood.

[3]  E. Clappier,et al.  Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia , 2008, The Journal of experimental medicine.

[4]  Stefan Fröhling,et al.  Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. , 2007, Cancer cell.

[5]  Govind Bhagat,et al.  Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia , 2007, Nature Medicine.

[6]  P. Marynen,et al.  The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. , 2007, Haematologica.

[7]  D. Gilliland,et al.  TG 101209 , a small molecule JAK 2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK 2 V 617 F and MPL W 515 L / K mutations , 2007 .

[8]  P. Westermark,et al.  Subcutaneous fat tissue for diagnosis and studies of systemic amyloidosis. , 2006, Acta histochemica.

[9]  Masaaki Nakamura,et al.  Transthyretin-related familial amyloidotic polyneuropathy. , 2005, Archives of neurology.

[10]  P. Marynen,et al.  Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia. , 2005, Haematologica.

[11]  M. Skinner,et al.  Identification of a novel substitution in the constant region of a gene coding for an amyloidogenic kappa1 light chain. , 1999, Biochimica et biophysica acta.

[12]  K. Olsen,et al.  The use of subcutaneous fat tissue for amyloid typing by enzyme-linked immunosorbent assay. , 1999, American journal of clinical pathology.

[13]  A. Solomon,et al.  Microextraction and purification techniques applicable to chemical characterization of amyloid proteins in minute amounts of tissue. , 1999, Methods in enzymology.

[14]  M. Schell,et al.  Light chain-associated amyloid deposits comprised of a novel kappa constant domain. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  K. Olsen,et al.  Constant Region of a κ III Immunoglobulin Light Chain as a Major AL‐Amyloid Protein , 1998, Scandinavian journal of immunology.

[16]  E. Arbustini,et al.  Familial AL-amyloidosis in three Italian siblings. , 1996, Haematologica.

[17]  R. Kyle,et al.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases. , 1995, Seminars in hematology.

[18]  J. Buxbaum.  Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease. , 1992, Hematology/oncology clinics of North America.

[19]  R. Kyle,et al.  Primary amyloidosis (AL) in families , 1986, American journal of hematology.

[20]  P. Thomas.  Genetic factors in amyloidosis. , 1975, Journal of medical genetics.